SCHEMBL24070798

SCHEMBL24070798

CN(C)C1CCN(c2nc(Cl)cc(Cl)c2C(=O)O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL3 Q96JM7 1/20 0.38
LMNA P02545 1/20 0.37
MAOB P27338 1/20 0.36
HTR6 P50406 1/20 0.36
FABP3 P05413 3/20 0.36
FABP4 P15090 3/20 0.36
FABP5 Q01469 3/20 0.36
CYP2C9 P11712 2/20 0.36
OPRK1 P41145 1/20 0.36
P2RX7 Q99572 2/20 0.36
PTPN11 Q06124 1/20 0.35
POLB P06746 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
EGFR P00533 1/20 0.35
ALK Q9UM73 1/20 0.35
PARP1 P09874 1/20 0.34
PARP2 Q9UGN5 1/20 0.34
MTOR P42345 1/20 0.34
ALDH1A1 P00352 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25698017 0.81 FABP3 (0.50) FABP3FABP4FABP5CYP2C9POLB
SCHEMBL30881533 0.78 KMT2A (0.44) L3MBTL3LMNAMAOBHTR6PTPN11
SCHEMBL25697994 0.77 NPSR1 (0.45) FABP3FABP4FABP5CYP2C9POLB
SCHEMBL24070271 0.76 KDM4E (0.41) LMNAFABP3FABP4FABP5CYP2C9
SCHEMBL24070559 0.74 SPR (0.41) FABP3FABP4FABP5CYP2C9PTPN11
SCHEMBL24069432 0.72 AKT1 (0.40) MTORMAPK1
SCHEMBL25698117 0.72 AKT1 (0.40) MTORMAPK1
SCHEMBL24070539 0.71 SPR (0.44) FABP3FABP4FABP5CYP2C9CYP3A4
SCHEMBL24069733 0.70 PIK3CA (0.37) MTOR
SCHEMBL24069564 0.69 SPR (0.46) FABP3FABP4FABP5CYP2C9CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115551867-B Fused tricyclic compounds, pharmaceutical compositions and uses thereof 劲方医药科技(上海)有限公司 2024-02-20 CN disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF GENFLEET THERAPEUTICS (SHANGHAI) INC. (CN) 2023-06-29 US disclosed
CN-115551867-A Fused tricyclic compound, pharmaceutical composition and application thereof 劲方医药科技(上海)有限公司 2022-12-30 CN disclosed
WO-2021239058-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF 劲方医药科技(上海)有限公司 2021-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203060-A1 FUSED TRICYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF KRAS, NRAS, TP53 L3MBTL3 3942/4885LMNA 2363/4885MAOB 3050/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.